The human epidermal growth factor receptor 2 (HER2). (Q37932507)

25 August 2017

1 reference

title

The human epidermal growth factor receptor 2 (HER2). (English)

1 reference

Erb-b2 receptor tyrosine kinase 2

25 August 2017

main subject

1 reference

Laura J Tafe

1

1 reference

25 August 2017

Gregory J Tsongalis

series ordinal

2

1 reference

25 August 2017

publication date

15 September 2011

1 reference

Clinical Chemistry and Laboratory Medicine

25 August 2017

published in

1 reference

25 August 2017

volume

50

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

23-30

1 reference

Untangling the ErbB signalling network

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Delay to formalin fixation effect on breast biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Emerging technologies for assessing HER2 amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

HER2-positive circulating tumor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.707

21 January 2018

Identifiers

DOI

10.1515/CCLM.2011.707

1 reference

25 August 2017

1 reference